New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 29, 2013
10:02 EDTCAT, GSK, CGV, TSN, PLXT, FITB, BRE, SPF, LEN, ERIC, ANF, HOV, SWIR, GPCOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Abercrombie & Fitch (ANF) upgraded to Outperform from Market Perform at BMO Capital... BRE Properties (BRE) upgraded to Neutral from Sell at Goldman... CGG Veritas (CGV) upgraded to Overweight from Neutral at JPMorgan... Caterpillar (CAT) upgraded to Outperform from Market Perform at BMO Capital... Ericsson (ERIC) upgraded to Buy from Hold at Deutsche Bank... Fifth Third Bancorp (FITB) upgraded to Outperform from Market Perform at Wells Fargo... Genuine Parts (GPC) upgraded to Buy from Hold at BB&T... Lennar (LEN) upgraded to Buy from Neutral at Compass Point... PLX Technology (PLXT) upgraded to Buy from Hold at Wunderlich... Sierra Wireless (SWIR) upgraded to Outperform from Sector Perform at RBC Capital... Standard Pacific (SPF) upgraded to Buy from Neutral at Compass Point... Tyson Foods (TSN) upgraded to Buy from Underperform at BofA/Merrill... Hovnanian (HOV) upgraded to Neutral from Sell at Compass Point... GlaxoSmithKline (GSK) upgraded to Overweight from Equal Weight at Barclays... Caterpillar (CAT) upgraded to Buy from Outperform at CLSA.
News For ANF;BRE;CGV;ERIC;FITB;GPC;LEN;PLXT;SWIR;SPF;TSN;HOV;GSK;CAT From The Last 14 Days
Check below for free stories on ANF;BRE;CGV;ERIC;FITB;GPC;LEN;PLXT;SWIR;SPF;TSN;HOV;GSK;CAT the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
April 17, 2014
15:55 EDTGSKGlaxoSmithKline, Genmab get FDA approval for Arzerra use
GlaxoSmithKline (GSK) and Genmab (GNMSF) announced that the U.S. FDA has approved a Supplemental Biologic License Application for the use of Arzerra, a CD20-directed monoclonal antibody, in combination with chlorambucil for the treatment of previously untreated patients with chronic lymphocytic leukemia for whom fludarabine-based therapy is considered inappropriate. The FDA approval of the first-line indication is based on results from a Phase III study which demonstrated statistically significant improvement in median progression-free survival in patients who received the combination of ofatumumab and chlorambucil compared to patients who received chlorambucil alone.
15:03 EDTGSKFDA grants wider approval for Glaxo's Arzerra in treatment of CLL
Subscribe for More Information
11:43 EDTGSKGlaxoSmithKline announces Canadian approval for Incruse Ellipta
GlaxoSmithKline announced that Incruse Ellipta has received market authorization in Canada for the long-term once-daily maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease, or COPD, including chronic bronchitis and emphysema. This is the first market authorization granted for this product anywhere in the world, the company noted.
07:20 EDTGSKGlaxoSmithKline opens internal probe of bribery allegations, WSJ says
Subscribe for More Information
06:37 EDTFITBFifth Third Bancorp reports Q1 EPS 36c, consensus 41c
Subscribe for More Information
April 16, 2014
12:16 EDTTSNPost likely to beat out Tyson for Michael Foods, WSJ says
Subscribe for More Information
05:29 EDTGPCGenuine Parts upgraded to Neutral from Sell at Goldman
Goldman upgraded Genuine Parts to Neutral citing valuation and expectations for growth acceleration. The firm raised its price target for shares to $88 from $84.
05:17 EDTERICEricsson announces initial five-year partnership with Mirantis
Mirantis and Ericsson entered into an initial five-year partnership to deploy Mirantis carrier-grade OpenStack software in the Ericsson cloud software platform used for telecommunications networks, internal data centers and cloud computing services that Ericsson will offer its customers. In addition to using Mirantis OpenStack for carrier-grade deployments, the Ericsson Global Services organization will deploy and integrate Mirantis OpenStack for the IT operation of mobile operators and service providers. This helps operators rationalize their IT infrastructure by delivering enterprise-grade cloud services to their users based on an open, widely supported standard. To support this initiative, Mirantis will also provide training, design and architecture assistance to Ericsson Global Services.
April 15, 2014
14:29 EDTGSKGlaxoSmithKline confirms FDA approval for Tanzeum
Subscribe for More Information
10:14 EDTGSKFDA approves Tanzeum to treat type 2 diabetes
The Food and Drug Administration approved Tanzeum subcutaneous injection to improve glycemic control, along with diet and exercise, in adults with type 2 diabetes. Tanzeum has a Boxed Warning to warn that tumors of the thyroid gland have been observed in rodent studies with some GLP-1 receptor agonists, but that it is unknown whether Tanzeum causes thyroid C-cell tumors, including a type of thyroid cancer called medullary thyroid carcinoma, in humans. Tanzeum should not be used in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2. The FDA approved Tanzeum with a Risk Evaluation and Mitigation Strategy, which consists of a communication plan to inform health care providers about the serious risks associated with Tanzeum. Tanzeum is manufactured by GlaxoSmithKline.
08:23 EDTGSKLeerink's pharma and biotech analysts hold an analyst/industry conference call
Subscribe for More Information
08:06 EDTGSKProsonix, Mylan enter licensing deal for generic version of Flixotide, Flovent
Subscribe for More Information
06:32 EDTGSKPatients paying much more for specialty drugs, NY Times says
The amount that patients with certain diseases must pay for specialty drugs has increased significantly, a research firm reported, according to The New York Times. Meanwhile, consumers' use of health care increased in 2013 for the firm time in three years, the newspaper quoted the firm, the IMS Institute for Healthcare Informatics, as saying. Publicly traded drug makers include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY). Publicly traded health insurers include AMERIGROUP (AGP), Aetna (AET), Centene (CNC), Cigna (CI), Health Net (HNT), Healthspring (HS), Humana (HUM), Molina Healthcare (MOH), UnitedHealth (UNH), WellCare (WCG) and WellPoint (WLP).Reference Link
April 14, 2014
10:09 EDTERICEricsson falls, levels to watch
Shares are down 3.5% in a narrow range of $12.60 at the low to $12.67 at the high. At current price resistance is at $13.13, the prior day close. Support is at $12.46.
06:40 EDTGSKGlaxoSmithKline paid bribes to Polish doctors to promote Seretide, BBC says
Subscribe for More Information
April 11, 2014
15:44 EDTTSNTyson, Post final contenders to buy Michael Foods, Reuters says
Michael Foods, the egg and dairy products maker that has been put up for sale by Goldman Sachs' (GS) private equity arm, is evaluating binding bids from Tyson (TSN) and Post (POST) and is near a deal to be sold to one of the two for close to $2.5B, according to Reuters, citing people familiar with the matter. Reference Link
13:36 EDTANFGap falls after experiencing sharp decline in March SSS
Subscribe for More Information
10:19 EDTERICQualcomm, Ericsson recommended by RBC Capital
Subscribe for More Information
09:09 EDTERICQualcomm Ericsson recommended for near-term at RBC Capital
Subscribe for More Information
April 10, 2014
11:42 EDTGSKReport claims Tamiflu, Relenza do little to prevent the spread of flu
Subscribe for More Information
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use